By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Apotex, Inc. et
al. v. Teva Pharmaceutical Industries, Ltd. et al.
0:13-cv-60601;
filed March 14, 2013 in the Southern District of Florida

• Plaintiffs: 
Apotex, Inc.; Apotex Corp.
• Defendants: 
Teva Pharmaceutical Industries, Ltd.; Teva Pharmaceuticals USA, Inc.

Infringement
of U.S. Patent No. 6,531,486 ("Pharmaceutical Compositions Comprising
Quinapril Magnesium," issued March 11, 2003) based on Teva's manufacture of
generic quinapril hydrochloride products (used to treat hypertension).  View the complaint here.

Bayer
Intellectual Property GmbH et al. v. Rea
1:13-cv-00324;
filed March 12, 2013 in the Eastern District of Virginia

• Plaintiffs: 
Bayer Intellectual Property GmbH; Bayer Pharma Aktiengesellschaft
• Defendant: 
Hon. Teresa Stanek Rea

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,273,876 ("Medicaments
Containing Vardenafil Hydrochloride Trihydrate," issued September 25,
2012).  View the complaint here.

Janssen
Products, L.P. et al. v. Hetero Drugs, Ltd. et al.
2:13-cv-01444;
filed March 8, 2013 in the District Court of New Jersey

• Plaintiffs: 
Janssen Products, L.P.; Janssen R&D Ireland
• Defendants: 
Hetero Drugs, Ltd.; Unit III; Invagen Pharmaceuticals, Inc.

Infringement
of U.S. Patent Nos. 7,126,015 ("Method for the Preparation of
Hexahydro-furo-[2,3-b]furan-3-ol," issued October 24, 2006) and 7,595,408
("Methods for the Preparation of
(3R,3aS,6aR)hexahydro-furo[2,3-b]furan-3-ol," issued September 29, 2009) in
conjunction with defendants' filing of an ANDA to manufacture a generic version
of Janssen's Prezista® (darunavir, used to treat human immunodeficiency virus
(HIV-1) infection).  View the complaint here.

Novartis
Pharmaceuticals Corp. et al. v. Alvogen Pine Brook Inc. et al.
1:13-cv-00370;
filed March 7, 2013 in the District Court of Delaware

• Plaintiffs: 
Novartis Pharmaceuticals Corp.; Novartis AG; Novartis Pharma AG; Novartis
International Pharmaceutical Ltd.; LTS Lohmann Therapie-Systeme AG
• Defendants: 
Alvogen Pine Brook Inc.; Alvogen Group Inc.

Novartis
Pharmaceuticals Corp. et al. v. Actavis Inc. et al.
1:13-cv-00371;
filed March 7, 2013 in the District Court of Delaware

• Plaintiffs: 
Novartis Pharmaceuticals Corp.; Novartis AG; Novartis Pharma AG; Novartis
International Pharmaceutical Ltd.; LTS Lohmann Therapie-Systeme AG
• Defendants: 
Actavis Inc.; Watson Pharmaceuticals Inc.; Watson Laboratories Inc.; Watson
Pharma Inc.

The
complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 6,316,023 ("TTS
Containing an Antioxidant," issued November 13, 2001) and 6,335,031 (same
title, issued January 1, 2002) following a Paragraph IV certification as part
of defendants' filing of an ANDA to manufacture a generic version of Novartis'
Exelon® Patch (rivastigmine tartrate, used to treat mild to moderate dementia
of the Alzheimer's type, and mild to moderate dementia associated with
Parkinson's disease).  View the Alvogen
complaint here.

Merck, Sharp
& Dohme Corp. et al. v. Hetero USA Inc. et al.
1:13-cv-01402;
filed March 7, 2013 in the District Court of New Jersey

• Plaintiffs: 
Merck, Sharp & Dohme Corp.; Bristol-Myers Squibb Co.; Bristol-Myers
Squibb Pharma Co.
• Defendants: 
Hetero USA Inc.; Hetero Labs Ltd. Unit-III

Infringement
of U.S. Patent Nos. 6,639,071 ("Crystal Forms of
(-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one,"
issued October 28, 2003) 6,939,964 (same title, issued September 6, 2005), and 6,673,372
("Crystalline Efavirenz," filed January 6, 2004) following a
Paragraph IV certification as part of Hetero's filing of an ANDA to manufacture
a generic version of BMS' Sustiva® (efavirenz, used to treat HIV
infection).  View the complaint here.